Share-based Payment Arrangement, Expense in USD of 10x Genomics, Inc. from 2017 to Q3 2025

Taxonomy & unit
us-gaap: USD
Description
Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.
Summary
10x Genomics, Inc. quarterly and annual Share-based Payment Arrangement, Expense history and change rate from 2017 to Q3 2025.
  • 10x Genomics, Inc. Share-based Payment Arrangement, Expense for the quarter ending 30 Sep 2025 was $25,264,000, a 25% decline year-over-year.
  • 10x Genomics, Inc. Share-based Payment Arrangement, Expense for the twelve months ending 30 Sep 2025 was $115,803,000, a 21% decline year-over-year.
  • 10x Genomics, Inc. annual Share-based Payment Arrangement, Expense for 2024 was $140,749,000, a 16% decline from 2023.
  • 10x Genomics, Inc. annual Share-based Payment Arrangement, Expense for 2023 was $166,950,000, a 22% increase from 2022.
  • 10x Genomics, Inc. annual Share-based Payment Arrangement, Expense for 2022 was $136,848,000, a 43% increase from 2021.
Source SEC data
View on sec.gov
Share-based Payment Arrangement, Expense, Trailing 12 Months (USD)
Share-based Payment Arrangement, Expense, Quarterly (USD)
Share-based Payment Arrangement, Expense, YoY Quarterly Change (%)
Share-based Payment Arrangement, Expense, Annual (USD)
Share-based Payment Arrangement, Expense, YoY Annual Change (%)

10x Genomics, Inc. Quarterly Share-based Payment Arrangement, Expense (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
Q3 2025 $115,803,000 $25,264,000 -$8,646,000 -25% 01 Jul 2025 30 Sep 2025 10-Q 07 Nov 2025 2025 Q3
Q2 2025 $124,449,000 $27,245,000 -$11,247,000 -29% 01 Apr 2025 30 Jun 2025 10-Q 08 Aug 2025 2025 Q2
Q1 2025 $135,696,000 $31,076,000 -$5,053,000 -14% 01 Jan 2025 31 Mar 2025 10-Q 09 May 2025 2025 Q1
Q4 2024 $140,749,000 $32,218,000 -$6,700,000 -17% 01 Oct 2024 31 Dec 2024 10-K 13 Feb 2025 2024 FY
Q3 2024 $147,449,000 $33,910,000 -$6,325,000 -16% 01 Jul 2024 30 Sep 2024 10-Q 07 Nov 2025 2025 Q3
Q2 2024 $153,774,000 $38,492,000 -$7,204,000 -16% 01 Apr 2024 30 Jun 2024 10-Q 08 Aug 2025 2025 Q2
Q1 2024 $160,978,000 $36,129,000 -$5,972,000 -14% 01 Jan 2024 31 Mar 2024 10-Q 09 May 2025 2025 Q1
Q4 2023 $166,950,000 $38,918,000 -$2,056,000 -5% 01 Oct 2023 31 Dec 2023 10-K 13 Feb 2025 2024 FY
Q3 2023 $169,006,000 $40,235,000 +$6,721,000 +20% 01 Jul 2023 30 Sep 2023 10-Q 29 Oct 2024 2024 Q3
Q2 2023 $162,285,000 $45,696,000 +$9,383,000 +26% 01 Apr 2023 30 Jun 2023 10-Q 08 Aug 2024 2024 Q2
Q1 2023 $152,902,000 $42,101,000 +$16,054,000 +62% 01 Jan 2023 31 Mar 2023 10-Q 30 Apr 2024 2024 Q1
Q4 2022 $136,848,000 $40,974,000 +$14,070,000 +52% 01 Oct 2022 31 Dec 2022 10-K 13 Feb 2025 2024 FY
Q3 2022 $122,778,000 $33,514,000 +$7,564,000 +29% 01 Jul 2022 30 Sep 2022 10-Q 03 Nov 2023 2023 Q3
Q2 2022 $115,214,000 $36,313,000 +$9,381,000 +35% 01 Apr 2022 30 Jun 2022 10-Q 04 Aug 2023 2023 Q2
Q1 2022 $105,833,000 $26,047,000 +$9,871,000 +61% 01 Jan 2022 31 Mar 2022 10-Q 04 May 2023 2023 Q1
Q4 2021 $95,962,000 $26,904,000 +$12,635,000 +89% 01 Oct 2021 31 Dec 2021 10-K 15 Feb 2024 2023 FY
Q3 2021 $83,327,000 $25,950,000 +$12,166,000 +88% 01 Jul 2021 30 Sep 2021 10-Q 03 Nov 2022 2022 Q3
Q2 2021 $71,161,000 $26,932,000 +$13,077,000 +94% 01 Apr 2021 30 Jun 2021 10-Q 09 Aug 2022 2022 Q2
Q1 2021 $58,084,000 $16,176,000 +$9,458,000 +141% 01 Jan 2021 31 Mar 2021 10-Q 05 May 2022 2022 Q1
Q4 2020 $48,626,000 $14,269,000 +$9,194,000 +181% 01 Oct 2020 31 Dec 2020 10-K 16 Feb 2023 2022 FY
Q3 2020 $39,432,000 $13,784,000 +$9,910,000 +256% 01 Jul 2020 30 Sep 2020 10-Q 05 Nov 2021 2021 Q3
Q2 2020 $29,522,000 $13,855,000 +$10,830,000 +358% 01 Apr 2020 30 Jun 2020 10-Q 06 Aug 2021 2021 Q2
Q1 2020 $18,692,000 $6,718,000 +$5,359,000 +394% 01 Jan 2020 31 Mar 2020 10-Q 07 May 2021 2021 Q1
Q4 2019 $13,333,000 $5,075,000 01 Oct 2019 31 Dec 2019 10-K 18 Feb 2022 2021 FY
Q3 2019 $3,874,000 +$3,285,000 +558% 01 Jul 2019 30 Sep 2019 10-Q 12 Nov 2020 2020 Q3
Q2 2019 $3,025,000 01 Apr 2019 30 Jun 2019 10-Q 12 Aug 2020 2020 Q2
Q1 2019 $1,359,000 01 Jan 2019 31 Mar 2019 10-Q 12 May 2020 2020 Q1
Q3 2018 $589,000 01 Jul 2018 30 Sep 2018 10-Q 12 Nov 2019 2019 Q3

10x Genomics, Inc. Annual Share-based Payment Arrangement, Expense (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
2024 $140,749,000 -$26,201,000 -16% 01 Jan 2024 31 Dec 2024 10-K 13 Feb 2025 2024 FY
2023 $166,950,000 +$30,102,000 +22% 01 Jan 2023 31 Dec 2023 10-K 13 Feb 2025 2024 FY
2022 $136,848,000 +$40,886,000 +43% 01 Jan 2022 31 Dec 2022 10-K 13 Feb 2025 2024 FY
2021 $95,962,000 +$47,336,000 +97% 01 Jan 2021 31 Dec 2021 10-K 15 Feb 2024 2023 FY
2020 $48,626,000 +$35,293,000 +265% 01 Jan 2020 31 Dec 2020 10-K 16 Feb 2023 2022 FY
2019 $13,333,000 +$10,675,000 +402% 01 Jan 2019 31 Dec 2019 10-K 18 Feb 2022 2021 FY
2018 $2,658,000 +$997,000 +60% 01 Jan 2018 31 Dec 2018 10-K 26 Feb 2021 2020 FY
2017 $1,661,000 01 Jan 2017 31 Dec 2017 10-K 27 Feb 2020 2019 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.